Ive seen drugs fast tracked for less impressive results .. we are talking Complete Remission in a few patients .. this is unheard of . Think Scarlett sold us short .. and still is ... accumulation at these levels is attractive but if insiders would buy some stock then it may show some confidence from their own pockets not just bonus shares... .. this has always made me cautious .. are they scared if they buy their cure that they will get sued for insider buying? something still smells
hopefully sign of things to come.. for GERNAfter Gilead Sciences won FDA approval for its cancer drug Zydelig last summer, some investors worried that sales of Johnson & Johnson (NYSE: JNJ ) and Pharmacyclics' (NASDAQ: PCYC ) Imbruvica, which is approved to treat the same indications as Zydelig, would falter. However, those worries appear overblown given that at the JP Morgan Healthcare Conference today Pharmacyclics issued rosy Imbruvica sales estimates for 2015 and forward looking guidance that suggests that Imbruvica is on track to be a top seller for J&J and Pharmacyclics for years to come.
First, a bit of background
Imbruvica's efficacy in early stage clinical trials prompted J&J to agree to pay Pharmacyclics $975 million in milestones, including $150 million upfront, as well as split profits on eventual sales, to co-develop the drug in 2011.
lots of nay sayers today.. this stock now has a lot of important deals done .. shorts nightmare.. and a few surprises left .. I think its 15 bucks by year end . We have Malaria and Shingles vaccine news and prophage.. plus many undisclosed qs21 programs .. and Herpv could be a huge surprise if booster does well..
Important is he mentioned money for maybe purchasing other drugs or tech .. etc
ceo blog site would be nice .. like agens .. Garo has .. http://www.thechairmansblog.com/agenus/garo-armen/2015-poised-another-transformative-year-agenus/
this part i liked the most "
Foundation for future Growth:
- Imetelstat primed to maximize value creation
- Financial ability to diversify through future acquisitions of new products, programs or companies
good question blackmarango .. i was #$%$ cause i saw the ceo of Agenus in mad money .. and the stock is up 25 pct after they did a deal with another pharma for their tech ..